Dr. Fred Sancilio reports

LOBE SCIENCES ANNOUNCES VALIDATION OF EUROPEAN UNITARY PATENT FOR DHA-BASED COMPOSITION FOR SICKLE CELL DISEASE

The European Patent Office has officially validated Lobe Sciences Ltd.'s European patent EP4117446 as a unitary patent.

Titled "A Composition Comprising Docosahexaenoic Acid ... for Sickle Cell Disease Treatment," the patent covers novel formulations combining DHA and ingredients specifically designed to address fatty acid deficiencies and related complications in sickle cell disease.

This unitary patent provides Lobe Sciences with intellectual property protection across 17 European Union member states, including Austria, Belgium, Bulgaria, Germany, Denmark, Estonia, Finland, France, Italy, Lithuania, Luxembourg, Latvia, Malta, Netherlands, Portugal, Romania (from Sept. 1, 2024), Sweden and Slovenia.

The validation marks a significant milestone in Lobe's efforts to broaden the global footprint of Altemia medical food, which is based on this composition. Altemia is a first-in-class emulsified oral formulation developed to restore red blood cell membrane integrity in patients with SCD. The formula leverages DHA and natural emulsifiers to improve bioavailability and effectiveness in managing long-chain fatty acid deficiencies -- a hallmark of SCD pathology.

"With this unitary patent in place, we are better positioned to protect and expand the reach of our proprietary SCD treatment technology throughout Europe," said Dr. Fred D. Sancilio,chief executive officer of Lobe Sciences. "This is an important step as we continue our mission to deliver nutritional and therapeutic innovations for patients with rare and neglected diseases."

About Lobe Sciences Ltd.

Lobe Sciences is a biopharmaceutical company focused on developing innovative therapies for rare and underserved conditions. Through its wholly owned subsidiary, Altemia Inc., and its majority-owned subsidiary, Cynaptec Pharmaceuticals Inc., Lobe is advancing a patented lipid-based platform for treating sickle cell disease and a novel oral analogue of psilocin -- conjugated psilocin -- targeted at chronic cluster headache and other neurological disorders. These programs address significant unmet medical needs with the potential to improve outcomes in both hematologic and neuropsychiatric patient populations.

We seek Safe Harbor.